Results 31 to 40 of about 461 (125)
Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. [PDF]
Int J Mol SciDiabetes mellitus is a devastating chronic metabolic disease. Since the majority of type 2 diabetes mellitus patients are overweight or obese, a novel term—diabesity—has emerged.
Eržen S +3 more
europepmc +2 more sources
Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions [PDF]
Modern MedicineObesity is a common and significant comorbidity of Polycystic Ovary Syndrome (PCOS), contributing to a range of metabolic and reproductive complications.
Dharani BHASKARAN, Suba ANGAPPAN
doaj +1 more source
AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY [PDF]
Journal of IMABAmylin is a peptide hormone co-synthesized with insulin in pancreatic beta cells at a ratio of 1:100. Notably, amylin has a pronounced tendency to form toxic amyloid fibrils, a characteristic relevant to its pathological role.
Nikolinka Koleva +2 more
doaj +1 more source
Uso de antidiabéticos no controlo da obesidade [PDF]
, 2023 Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, 2023, Universidade de Lisboa, Faculdade de Farmácia.Tanto a diabetes como a obesidade são consideradas epidemias.
Araújo, Daniela Laneiro
core +2 more sources
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
British Journal of Pharmacology, EarlyView.Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Amylin analogues as a novel perspective in anti‐obesity therapy
British Journal of Pharmacology, EarlyView.Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source
Peripheral targets for neuropathic pain
British Journal of Pharmacology, EarlyView.Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Laura Busk‐Cirera +6 more
wiley +1 more source
Central nervous system pathways targeted by amylin in the regulation of food intake [PDF]
Amylin is a peptide hormone co-released with insulin from pancreatic β-cells during a meal and primarily serves to promote satiation. While the caudal hindbrain was originally implicated as a major site of action in this regard, it is becoming ...
Le Foll, Christelle; https://orcid.org/ +1 more
core +1 more source
Pharmacological Treatment of Obesity: A Review of Current and Future Methods [PDF]
Introduction and objective Obesity poses a significant public health challenge due to its association with an elevated risk of various chronic diseases, including cardiovascular conditions, type 2 diabetes, and overall mortality.
Angelina Lęgas +9 more
core +4 more sources